Place de la radiothérapie (et chimioradiothérapie) dans les cancers localement avancés ou borderline. Quelles perspectives ?

No abstract is available for this paper.

• Publication year

  2015

• Venue

  ONCOLOGIE

• Publication date

  2015-12-14

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/s10269-015-2561-9
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial

  2013cited by this paper
• Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

  2013cited by this paper
• Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.

  2013cited by this paper
• Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety

  2013cited by this paper
• Sequential neoadjuvant chemotherpy with nab-paclitaxel plus gemcitabine and FOLFIRINOX in locally advanced pancreatic cancer (LAPC): A PILOT study.

  2013cited by this paper
• Radiotherapy of the pancreas: state of the art in 2012.

  2012cited by this paper
• Neoadjuvant therapy with nanoparticle albumin-bound (nab)-paclitaxel to enhance the resectability of locally advanced pancreatic cancer (LAPC).

  2012cited by this paper
• [Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis].

  2012cited by this paper
• FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

  2012cited by this paper
• Randomized multicenter phase III study in patients with locally advanced adenocarcinoma of the pancreas: Gemcitabine with or without chemoradiotherapy and with or without erlotinib-LAP 07 study.

  2011cited by this paper
• Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.

  2011cited by this paper
• [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies.

  2011cited by this paper
• A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer

  2011cited by this paper
• Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer.

  2011cited by this paper
• Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.

  2011cited by this paper
• Stereotactic body radiation therapy for gastrointestinal malignancies.

  2011cited by this paper
• Chemoradiotherapy in the Management of Locally Advanced Pancreatic Carcinoma:A Qualitative Systematic Review

  2010cited by this paper
• Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial.

  2010cited by this paper
• Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.

  2010cited by this paper
• Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

  2010cited by this paper
• Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer.

  2009cited by this paper
• DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

  2009cited by this paper
• Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas

  2009cited by this paper
• Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.

  2009cited by this paper
• WITHDRAWN: Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer.

  2009cited by this paper
• Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer.

  2008cited by this paper
• A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.

  2008cited by this paper
• Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans

  2008cited by this paper
• Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study.

  2008influential reference
• Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.

  2007cited by this paper
• Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy

  2007cited by this paper
• A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.

  2007cited by this paper
• Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.

  2007cited by this paper
• Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy

  2006cited by this paper
• Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer.

  2006cited by this paper
• HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo.

  2005cited by this paper
• Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

  2005cited by this paper
• Erlotinib and Chemoradiation Followed by Maintenance Erlotinib for Locally Advanced Pancreatic Cancer: A Phase I Study

  2005cited by this paper
• Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.

  2004cited by this paper
• Epidemiology and risk factors

  2002cited by this paper
• Pancreatic cancer.

  2002cited by this paper
• The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells.

  2002cited by this paper
• Chemo-radiotherapy for localized pancreatic cancer: increased dose intensity and reduced acute toxicity with concomitant radiotherapy and protracted venous infusion 5-fluorouracil.

  1998cited by this paper
• Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

  1997cited by this paper
• Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group.

  1988cited by this paper
• Cancer of the pancreas: 50 years of surgery

  1987cited by this paper
• Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study.

  1985cited by this paper
• Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5‐fluorouracil), and high dose radiation + 5‐fluorouracil. The gastrointestinal tumor study group

  1981cited by this paper
• Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial.

  1981cited by this paper
• [Cancer of the pancreas].

  1965cited by this paper

• No citing papers are available for this paper.